Allied Biotech Corporation (TPEX:1780)
Taiwan · Delayed Price · Currency is TWD 25.45
-0.65 (-2.49%)
Jan 22, 2026, 1:52 PM CST
Allied Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 94.59 | 100.94 | 97.41 | 146.74 | 13.04 | 79.47 | Upgrade |
Depreciation & Amortization | 61.14 | 61.94 | 69.45 | 71.76 | 65.24 | 61.63 | Upgrade |
Loss (Gain) From Sale of Assets | 0.86 | - | - | 1.59 | - | 0.23 | Upgrade |
Loss (Gain) From Sale of Investments | - | - | - | - | - | -2.33 | Upgrade |
Provision & Write-off of Bad Debts | 0.8 | - | - | 2 | - | 1.17 | Upgrade |
Other Operating Activities | -6.21 | -2.7 | -16.62 | 31.82 | -9.13 | 2.33 | Upgrade |
Change in Accounts Receivable | -2.65 | -21.69 | 8.62 | -16.2 | 13.7 | -43.24 | Upgrade |
Change in Inventory | 20.75 | 73.94 | -5 | -88.39 | -22.84 | -46.29 | Upgrade |
Change in Accounts Payable | -1.6 | -1.4 | -10.69 | -0.41 | 10.7 | 3.78 | Upgrade |
Change in Unearned Revenue | -2.59 | -2.04 | 3.39 | -0.34 | 0.88 | -0.06 | Upgrade |
Change in Other Net Operating Assets | 3.59 | 14.8 | -8.95 | 15.7 | 0.83 | 2.78 | Upgrade |
Operating Cash Flow | 168.68 | 223.79 | 137.62 | 164.27 | 72.43 | 59.48 | Upgrade |
Operating Cash Flow Growth | -22.67% | 62.62% | -16.23% | 126.81% | 21.77% | -48.92% | Upgrade |
Capital Expenditures | -31.05 | -26.81 | -47.91 | -54.66 | -49.99 | -56.82 | Upgrade |
Sale of Property, Plant & Equipment | - | - | - | 0.11 | - | 0.01 | Upgrade |
Investment in Securities | -19.47 | 97.37 | 6.98 | 273.57 | -130.95 | 91.11 | Upgrade |
Other Investing Activities | 0 | -0.02 | -0.01 | - | - | -0.45 | Upgrade |
Investing Cash Flow | -50.51 | 70.55 | -40.94 | 219.02 | -180.94 | 33.84 | Upgrade |
Short-Term Debt Issued | - | 170 | - | - | 265 | 320 | Upgrade |
Long-Term Debt Issued | - | 58.87 | - | 107.68 | - | 144.3 | Upgrade |
Total Debt Issued | 110 | 228.87 | - | 107.68 | 265 | 464.3 | Upgrade |
Short-Term Debt Repaid | - | - | -20 | -390 | - | - | Upgrade |
Long-Term Debt Repaid | - | -82.99 | -24.17 | -132.32 | -24.76 | -168.74 | Upgrade |
Total Debt Repaid | -24.08 | -82.99 | -44.17 | -522.32 | -24.76 | -168.74 | Upgrade |
Net Debt Issued (Repaid) | 85.92 | 145.88 | -44.17 | -414.64 | 240.24 | 295.56 | Upgrade |
Common Dividends Paid | -96.02 | -81.42 | -114.46 | -47.68 | -76.12 | -94.89 | Upgrade |
Other Financing Activities | 0.73 | 0.48 | 0.3 | 0.32 | 0.12 | - | Upgrade |
Financing Cash Flow | -9.38 | 64.94 | -158.33 | -462 | 164.24 | 200.67 | Upgrade |
Foreign Exchange Rate Adjustments | -0.47 | 0.56 | 0.39 | 1.07 | -1.82 | 0.7 | Upgrade |
Net Cash Flow | 108.33 | 359.84 | -61.26 | -77.64 | 53.91 | 294.69 | Upgrade |
Free Cash Flow | 137.63 | 196.98 | 89.71 | 109.62 | 22.44 | 2.66 | Upgrade |
Free Cash Flow Growth | -27.53% | 119.58% | -18.16% | 388.49% | 744.88% | -96.42% | Upgrade |
Free Cash Flow Margin | 16.75% | 24.41% | 12.45% | 15.29% | 3.32% | 0.43% | Upgrade |
Free Cash Flow Per Share | 1.43 | 2.04 | 0.94 | 1.14 | 0.23 | 0.03 | Upgrade |
Cash Interest Paid | 17.2 | 13.58 | 12.87 | 11.65 | 11.06 | 8.91 | Upgrade |
Cash Income Tax Paid | 30.27 | 32.55 | 40.65 | 5.66 | 13.88 | 20.34 | Upgrade |
Levered Free Cash Flow | - | 135.02 | 33.04 | 17.52 | 65.85 | -15.8 | Upgrade |
Unlevered Free Cash Flow | - | 143.74 | 41.13 | 24.86 | 72.88 | -10.17 | Upgrade |
Change in Working Capital | 17.5 | 63.61 | -12.63 | -89.63 | 3.28 | -83.02 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.